Safety and Immunogenicity of GS-1966+GS-1144 Vaccines in Virally Suppressed Adults Living With HIV-1: A Phase 1b, Randomized, Placebo-Controlled Study

Conference Reports for NATAP

HIV Drug Therapy Glasgow 2024
10-13 November


Safety and Immunogenicity of GS-1966+GS-1144 Vaccines in Virally Suppressed Adults Living With HIV-1: A Phase 1b, Randomized, Placebo-Controlled Study

	HIV Drug Therapy Glasgow 2024; November 10-13; Glasgow, UK